Southeast Asia's medical device supply chain urgently needs restructuring: KPMG points out that fragmentation and internal complexity are growth bottlenecks.

Growth Potential and Real-World Challenges

Southeast Asia is becoming a key growth market for global medical device companies. According to the latest KPMG report, the region has a population of over 700 million, and government healthcare policies are continuously expanding infrastructure and surgical volumes, creating strong demand for the medical device industry. Global giants expect sustained double-digit growth in Southeast Asia and plan to increase investments in manufacturing and distribution.

However, KPMG warns that if the supply chain is not restructured specifically, it will become a major constraint to growth in the short term. The report identifies two core obstacles: internal complexity and external fragmentation.

Internal Complexity: SKU Proliferation and Operational Pressure

In many Southeast Asian markets, the number of product SKUs is expanding, partly due to government tendering decisions that sustain demand for older products. This increases planning complexity, safety stock levels, and working capital investment. Companies must maintain multi-variety inventory across multiple markets, putting pressure on capital efficiency.

External Fragmentation: Regulatory Disparities and Distribution Dependence

Despite frameworks such as the ASEAN Medical Device Directive and the Regional Comprehensive Economic Partnership Agreement, enforcement varies across countries with differing regulations and inconsistent customs procedures. At the same time, the region remains highly dependent on a distributor model, but most partnerships are loose and lack performance orientation. This results in poor execution consistency, increased compliance risks, and difficulty penetrating second- and third-tier cities.

Path Forward: Three-Pronged Approach

KPMG proposes three priority actions for medical device companies:

• Enhance end-to-end supply chain visibility: Leverage demand sensing, control towers, integrated business planning, and direct consumption data from hospital apps and digital ordering platforms to build a transparent supply chain.
• Strengthen distributor collaboration: Shift from loose cooperation to structured, performance-based partnerships with clear KPIs, governance mechanisms, and compliance requirements.
• Selective localization: Avoid replicating full manufacturing setups in every country; perform limited localization only for bidding, local content, or regulatory requirements, otherwise it will lead to process duplication and cost increases.

Industry Collective Action: Beyond Individual Company Limitations

KPMG emphasizes that transformation by individual companies alone cannot offset the costs and delays from regulatory fragmentation. Real change requires regional regulatory coordination: promoting mutual recognition of regulations, unifying documentation, and reducing redundant audits.

Southeast Asia has the elements to become an efficient and resilient medical device supply chain hub—strong demand, evolving policy frameworks, and improved operational capabilities. But ultimately, the winners will be those companies that design their supply chains to address fragmented regulations and shared demands.